Abstract: An optical film, comprising a substrate, wherein a first plurality of multi-faceted recesses are formed on the substrate, wherein the plurality of multi-faceted recesses are capable of scattering lights that enter into a second surface of the substrate, said first surface and said second surface are two opposite surfaces of the substrate.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: A composite optical film, comprising: a quantum-dot film and a first optical film disposed over the quantum-dot film, wherein a first plurality of multi-faceted recesses are formed on a first surface of the first optical film, wherein each multi-faceted recess comprises a shape of a reversed cone.

Abstract: The present invention discloses a quantum-dot composite film comprising: a quantum-dot prism film, comprising a quantum-dot layer and a first plurality of prisms disposed over the quantum-dot layer, wherein a first optical prism film and a second optical prism film are disposed over the quantum-dot prism film for increasing the brightness level of the quantum-dot prism film.

Abstract: A composite quantum-dot optical film comprises a quantum-dot layer and a composite structure disposed on the quantum-dot layer, wherein the composite structure comprises a first substrate, a second substrate, and a first barrier layer, wherein each of the first substrate and the second substrate comprises a polymer material, wherein the barrier layer being made of organic material and capable of being water-resistant is disposed between the first substrate and the second substrate.

Abstract: A quantum-dot optical film comprises: a binder, wherein a plurality of quantum dots, and a plurality of clay fragments are dispersed in the binder, wherein each of the clay fragments is capable of being water-resistant and oxygen-resistant.

Abstract: A quantum-dot optical film comprising a quantum-dot layer, a first base film and a first coating layer, wherein the first coating layer is coated on the base film, wherein the first coating layer is disposed on a top surface of the quantum-dot layer, the first coating layer comprising a first polymer and clay fragments dispersed in the first polymer for being water-resistant and oxygen-resistant.

Abstract: The present disclosure relates to a field of semiconductor manufacturing technology, and in particular to a method for forming a semiconductor structure and a semiconductor structure. The method for forming the semiconductor structure includes: a substrate is placed in a reaction chamber, and the substrate includes at least one first conductive structure, a surface of the substrate is covered with an isolation layer, a surface of the isolation layer is covered with a first mask layer, and the first mask layer includes at least one etching window exposing the isolation layer; the isolation layer, a part of the substrate and a part of each of the at least one first conductive structure are etched along the at least one etching window according to preset etching parameters to form at least one trench; a barrier layer is formed; and at least one second conductive structure is formed.

Abstract: Disclosed herein are compositions and methods for treating cancer patients who have been previously treated with one or more chemotherapeutic agents and have developed at least partial resistance to such chemotherapeutic agents. Also disclosed are methods for selecting compounds suitable for treatment of cancer in a patient who has become resistant to an inhibitor of a receptor tyrosine kinase (RTK).

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: The present invention discloses a quantum-dot film, wherein the quantum-dot film comprises a binder and a plurality of quantum dots dispersed in the binder, wherein the plurality of quantum dots are capable of being water-resistant and oxygen-resistant.

Abstract: Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Abstract: Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.